Stay up to date with the latest news and activities at AKESOgen.

bio1

AKESOgen to host and sponsor Industry tour on behalf of Georgia Bio

Please join Georgia Bio’s Emerging Leaders Network on their Industry Tour for an inside look of AKESOgen, a premier provider of genetic analysis.

This industry tour will provide participants an inside look of AKESOgen, a leader in personalized medicine and genomics.  Equipped with industry experts, AKESOgen provides high quality genomic analysis services, performing over 21,000 whole genome genotyping monthly. It is the only facility in the United States that has developed and performs clinical commercial copy number alteration (CNA) microarray analysis for formalin-fixed, paraffin-embedded (FFPE) tissue samples on Illumina platforms. AKESOgen provides contract research, clinical diagnostic and clinical trial services to pharmaceutical, biotech, academic, and government research institutions.  The company supported over 100 academic investigators in 2014.

All participants should be dressed smart casual with closed toe shoes.

To register for this event and further details please go to: http://www.gabio.org/events/event_details.asp?id=600212

When:
Wednesday, September 09, 2015
10:30 am – 12:30 pm

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
bio1

2014 BioGENEius Winner Kayla Evans Visits AKESOgen

February, 11, 2015 - The 2014 Georgia BioGENEius Winner, Kayla Evans visited Georgia Bio AKESOgen.

The visit began with an introduction of the company and then the small group including Ms. Evans and her parents, and Georgia BioEd Institute Program Director, Melissa Nikolic, proceeded to tour the facility. Ms. Evans learned about opportunities in the life sciences field and heard from AKESOgen employees about the research and technology at the company.

The BioGENEius Challenge is the premier competition for high school students that recognizes outstanding research in biotechnology.  It promotes excellence and enables students to continue research in biotechnology and design an original independent research project.  Applications are now being accepted for the 2015 Challenge. Click here to learn more.

AKESOgen were delighted to sponsor Ms. Evans attendance and presentation at the Georgia Bio Awards Dinner on January 22, 2015. 

IMG_0187

Pictured: Mark Bouzyk Ph.D. Co-Founder & CSO, AKESOgen; Kayla Evans; and Melissa Nikolic, Georgia BioEd Institute Program Director

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
bio1

AKESOgen receives a prestigious Deal of the Year Award at the Annual Georgia Bio Awards Night

IMG_2374

AKESOgen receives a prestigious Deal of the Year Award at the Annual Georgia Bio Awards Night

Atlanta, USA – 22nd January 2015– AKESOgen was recognized by its peers from the Biotechnology industry at a gala event at the Fox Theatre in Atlanta for its public/ private partnership alliance and outstanding work with the US Department of Veteran’s Affairs.

“We are delighted to be honored by our peers and are particularly proud to be chosen amongst a stellar group of organizations that are true world leaders in the global market and are great examples of the thriving biotechnology community in the state of Georgia” said Bob Boisjoli, CEO of AKESOgen.

The US Department of Veterans Affairs Million Veteran Program is the largest genetic initiative ever undertaken in the US and its visionary genomics and genetics approach will provide new insights about how genes affect health. The goal is to improve healthcare for veterans by understanding the genetic basis of many common conditions. The data will ultimately be beneficial to the healthcare of all veterans and of the wider community.

“We are extremely excited to support the VA for this unique endeavor as we provide genetic data of the highest quality to the VA. AKESOgen is delivering over 800,000 genetic datapoints to the VA for each of the patients it provides analysis making up many terabytes of information each year” commented Mark Bouzyk, CSO of AKESOgen.

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, sequencing, genotyping, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Georgia Bio (www.gabio.org) is the private, non-profit association whose members include pharmaceutical, biotechnology and medical device companies, medical centers, universities and research institutes, government groups and other business organizations involved in the development of life sciences related products and services.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Maria Thacker, VP of Operations. Georgia Bio. +1 404-920-2042 (office), or maria.thacker@gabio.org

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
SBC Logo

Shanghai Biotechnology Corporation and AKESOgen form Alliance to Provide Transnational Genomics Services

Partnership will enable and enhance standardized American-Asian protocols

Shanghai, CN and Atlanta, USA – 13th January, 2015–.  Shanghai Biotechnology Corporation (SBC), a leader in Customer-oriented R&D biomarker service provider, and AKESOgen, a respected genetics, genomics and bio repository services provider, announced they will form a strategic business development alliance which will enable joint projects with pharmaceutical and biotechnology clients in the USA and Asia.  The partnership will bring together AKESOgen´s proprietary know-how in sequencing, genotyping, methylation profiling, expression profiling, PCR, qPCR, copy number variation and DNA and RNA extractions, with SBC’s extensive expertise in performing comprehensive genomic and pharmacogenomic services.

“Shanghai Biotechnology Corporation’s services are very complimentary to AKESOgen’s.  This partnership will allow us to jointly develop important opportunities that span the Asian and US genomics markets” said Bob Boisjoli, CEO of AKESOgen.

Dr. Huasheng Xiao, CEO of Shanghai Biotechnology Corporation commented, “AKESOgen and its team of world class experts in the field of genomics are a natural fit for SBC to enhance our service offerings and presence in the US market.”

About Shanghai Biotechnology Corporation

SBC is a leading Chinese global biotech service provider in genomic and genetic biomarker discovery and development.  The core service business of SBC is to provide highly standardized development and application of genomics/genetics biomarkers for the international pharmaceutical and diagnostic industry. The company has supported thousands of R&D projects for pharma, biotech and academia since 2001. SBC has multidisciplinary teams experienced in obtaining, integrating and analyzing complex data using the most advanced technology to explore the role of genetic variation in individual responses to drugs and susceptibility to certain diseases. For more information, visit http://www.shanghaibiotech.com/

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Yuhua Li, MD PhD, Shanghai Biotechnology Corporation. +86-21-51320288, ext 8219 (office), or yuhua_li@shbiochip.com

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

 

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
tricon

AKESOgen attends Molecular Med TRI-CON 2015

Scientists from AKESOgen attended at the Moscone North Convention Center, San Francisco, CA from February 15-20, 2015. Please email info@akesogen.com or call 770 542 0890 if you want to follow up with a delegate.

images

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
bio1

AKESOgen honored in January 2015 Georgia BIO Awards

Media contact:
Maria Thacker Goethe
404-920-2042
maria.thacker@gabio.org

Georgia Bio Deals of the Year
Spotlight Financings, Acquisitions and Collaboration

ATLANTA, GA (December 19, 2014) — Georgia Bio announced its 2015 Deals of the Year for pharmaceutical, biotechnology, healthcare IT and medical device companies in three categories – private financing, acquisitions and public/private collaboration – reflecting a broad range of activity. The annual Deal of the Year awards recognize transactions by life sciences companies in Georgia such as financings, partnering agreements and government grants that are significant to the state’s industry development.

Deals of the Year are awarded to one or more companies or institutions for the most significant financial or commercial transactions closed from November 1, 2013-October 31, 2014. The recipients will receive their awards at the Georgia Bio Annual Awards Dinner January 22, 6 pm to 9 pm, at Atlanta’s Fox Theater. Now in its 17th year, the Georgia Bio annual awards dinner brings together industry leaders to advance the growth of the life sciences industry and foster strategic partnerships that can create a healthier world. Other leading companies, executives, researchers and dedicated individuals will receive Georgia Bio Awards at the dinner. Learn more and register at www.gabio.org/awards.

The recipients are: Alimera Sciences, Clearside Biomedical, St. Jude Medical/CardioMEMS, Varian Medical Systems/Velocity Medical Solutions, Immucor, and AKESOgen/ VA Million Veteran Program.

Private Financing
Alimera Sciences
Alimera was successful in raising $122.5 million during 2014 for the continued commercialization of its lead product, ILUVIEN, in 17 countries in Europe as well as a planned commercial launch in the United States in 1Q 2015. Alimera secured $37.5 million in a private placement in February followed by a $35 million venture debt facility through Hercules Technology Growth Capital in April. In addition, Alimera recently announced a $50 million equity financing in November with Deerfield Management. Alimera received FDA approval of ILUVIEN on September 26, 2014.

ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first Diabetic Macular Edema treatment to deliver 36 months of continuous, low-dose corticosteroid therapy with a single injection. DME is the major cause of vision loss in people with diabetic retinopathy. People with diabetes have a 10 percent risk of developing the condition during their lifetime and an estimated 21 million people around the globe have DME. This number will only continue to grow as the number of people with type 2 diabetes is rapidly increasing in every country. Current estimates are that there will be 1.5 times the number of diabetic patients in 20 years’ time.

Alimera Sciences, Inc. employs approximately 100 employees with offices in Alpharetta, London, Berlin, Paris,
and Lisbon. To learn more, visit www.alimerasciences.com

Clearside Biomedical
Clearside Biomedical, Inc., in September 2014, announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.

Headquartered in Alpharetta, GA, Clearside Biomedical is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside’s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space with Clearside’s proprietary microinjector.

Clearside is using the proceeds from this financing to fund three programs. They are currently advancing two product candidates through the clinical trial process. CLS1001, for the treatment of macular edema following uveitis, is enrolling patients in a Phase 2 clinical trial and CLS1003, for the treatment of macular edema following retinal vein occlusion, has initiated patient enrollment in a Phase 2 clinical trial. Clearside also has a drug development program for the treatment of wet AMD in preclinical testing. To learn more, visit http://clearsidebio.com/

Acquisitions
St. Jude Medical and CardioMEMS
CardioMEMS, Inc., led by Founder and CEO, Jay Yadav, MD, developed the FDA approved CardioMEMS HF System which uses a miniaturized, wireless sensor to directly measure pulmonary artery pressure and transmit the information to a database remotely. Non-invasive, real-time monitoring of these pressures helps nurses and physicians monitor and intervene at the earliest stages of heart failure, so that the likelihood of hospitalization is reduced.

The CardioMEMS HF System can help healthcare providers more effectively manage medications and other forms of treatment before heart failure symptoms escalate. Clinical testing demonstrated that use of the device resulted in a decrease of hospitalization rates among heart failure patients at 6 months and 15 months by 28 percent and 37 percent, respectively.

In June of 2014, CardioMEMS was acquired by St. Jude Medical, Inc., a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases, for more than $450 million. The acquisition was in line with St. Jude Medical’s on-going commitment to provide innovative medical device solutions that reduce the burden of complex diseases like heart failure, both on patients and healthcare systems.To learn more, visit http://www.sjm.com/cardiomems

Varian Medical Systems & Velocity Medical Solutions
Varian Medical Systems, a leading supplier of equipment and software for treating cancer with radiotherapy, radiosurgery, brachytherapy, and proton therapy, announced in April 2014 that Varian had acquired specific assets of Velocity Medical Solutions, LLC, an Atlanta-based developer of specialized software for cancer clinics.

The acquisition included software designed to access and aggregate unstructured treatment and imaging data from diverse systems to show a comprehensive view of a cancer patient’s diagnostic imaging and treatment history, regardless of where they were treated or what technology was used. By organizing patient data and making it available in one place, the Velocity software was designed to help clinicians make more informed treatment decisions. Varian continues to develop the Velocity software platform with the Velocity team in Atlanta.

The Velocity organization was founded by leading clinicians who developed innovative and powerful tools that transform unstructured data into useful clinical knowledge. The Velocity software, which at that point was already in use at over 200 cancer treatment centers worldwide, enables clinicians to easily collect, integrate, and share data from CT, PET, and MR images and diverse treatment systems for close collaboration with referring physicians and others on the care team. To learn more, visit https://www.varian.com/velocity.

Immucor Acquires Sentilus
Immucor, Inc., led by CEO William A. Hawkins III, is a global leader in transfusion and transplantation diagnostics. Headquartered in Norcross, GA, the Company completed six transactions during 2014 focused on enhancing its product offering and expanding its geographic footprint.

During May, Immucor acquired Organ-i, Inc., a privately-held company focused on developing non-invasive tests to monitor and predict organ health for transplant recipients. In October, Immucor announced a collaboration with privately held Sirona Genomics, Inc., which was spun out of the Stanford Genome Technology Center at Stanford University. As part of the collaboration Immucor will provide development funding to support the commercialization of Sirona’s human leukocyte antigen (HLA) typing offering using next generation sequencing. Immucor retains an exclusive option to acquire the company. Both transactions strengthen Immucor’s transplantation diagnostics portfolio. Also during October, Immucor acquired privately held Sentilus, Inc., which was spun out of Duke University. This acquisition strengthens Immucor’s transfusion diagnostics portfolio with a novel, inkjet-printed antibody microarray-based technology. Additionally during 2014, Immucor also acquired its transplantation diagnostics distributors in Italy, the United Kingdom and India.

Immucor’s mission is to create a world where anyone, anywhere in need of blood or an organ gets the right blood or organ that is safe, accessible and affordable. To learn more, visit www.immucor.com.

Public/Private Collaboration
AKESOgen & VA Million Veteran Program
The US Department of Veterans Affairs Million Veteran Program is the largest genetic initiative ever undertaken in the US and its visionary genomics and genetics approach will provide new insights about how genes affect health. The goal is to improve healthcare for veterans by understanding the genetic basis of many common conditions. The data will ultimately be beneficial to the healthcare of all veterans and of the wider community. We are delighted to support the VA for this unique endeavor as we provide genetic data of the highest quality to the VA. AKESOgen is delivering over 800,000 genetic datapoints to the VA for each of the patients it provides analysis making up many terabytes of information each year. AKESOgen provides genomics services for the clinical applications and also for the research and development market, including biobanking, DNA/RNA extraction, and genetic technologies. Founded in 2010, our company services to the clinical, pharmaceutical, biotechnology, academic, and government sectors. AKESOgen received $7.5 M for year one (out of a 5 year award). To learn more, visit www.akesogen.com.

For a list of past Georgia Bio Award recipients, click here.

Georgia Bio (www.gabio.org) is the private, non-profit association whose members include pharmaceutical, biotechnology and medical device companies, medical centers, universities and research institutes, government groups and other business organizations involved in the development of life sciences related products and services.

Note to Editors: Credentialed members of the news media are invited to attend. Registration is complimentary. Please contact Maria Thacker (404-920-2042; maria.thacker@gabio.org).

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
Untitled3

AKESOgen receives State of California Licensure to offer Clinical Testing

Atlanta, GA – 2nd October, 2014– Personalized medicine and genomics company AKESOgen today announced that its CLIA-compliant laboratory has received the California Clinical Laboratory License, which will allow the company to perform its oncology testing services on patient samples from the state of California.

The Georgia based company said in a statement that it believes its cytogenomics tests for a wide spectrum of solid and liquid tumors will be of particular benefit to the state –as the test is offered as a complement to NGS clinical oncology testing.

“This endorsement by the State of California for AKESOgen provide our comprehensive oncology tests and services gives AKESOgen access to the single largest US oncology diagnostics market, and will help accelerate our commercial growth in this sector.” said Mark Bouzyk, CSO of AKESOgen.

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail

AKESOgen helps Toronto Police Service Solve Cold Cases

TPS recently partnered with two US partners —AKESOgen, a genomics company; and Identitas, a DNA profiling company. Neither of these companies have worked with police before, Borg says, but they say they’ll be able to do something unique with TPS’s cold case DNA evidence: create police sketches. If all goes as planned, Borg says TPS will be able to pinpoint ancestral information, hair color, eye color, and ethnicity of the people whose DNA evidence was found at murder scenes years ago.  More…

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail
clinicaltestingpic

AKESOgen launches Clinical Oncology Molecular Cytogenomics Microarray Test

Atlanta, GA – 1st April, 2014– Personalized medicine and genomics company AKESOgen today announced that its CLIA-compliant laboratory has launched a new clinically validated cytogenomics microarray test. The test measures Copy Number Alterations (CNAs) across the genome utilizing Illumina’s CytoSNP 850K beadarray. The assay is validated across a wide spectrum of cancers e.g. solid tumors including breast, lung, brain and liquid tumors such as leukemias and lymphomas. It is also validated using a wide variety of starting materials including FFPE tissue, blood and bone marrow.

“We are delighted to launch our cytogenomic array test as it has enormous clinical utility – for prognosis and clinical work up. We believe we are the only commercial laboratory in the USA running this test on the Illumina platform utilizing FFPE tissue.” said Mark Bouzyk, CSO of AKESOgen.

About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.

Media Contacts:

Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or mbouzyk@akesogen.com

Share this facebooktwittergoogle_plusredditlinkedinmailfacebooktwittergoogle_plusredditlinkedinmail